Immunotherapy of myelodysplastic syndrome: You can run, but you can't hide

Research output: Contribution to journalArticlepeer-review

Abstract

The hypomethylating agent decitabine induces expression of the cancer/testis antigen NY-ESO-1 in the myeloid cells of patients with myelodysplastic syndrome (MDS). Patients with MDS treated with decitabine and an NY-ESO-1 vaccine developed NY-ESO-1–specific T-cell responses directed against their abnormal myeloid cells, raising hopes for combinatorial immunotherapy of this disease.

Original languageEnglish (US)
Pages (from-to)991-993
Number of pages3
JournalClinical Cancer Research
Volume24
Issue number5
DOIs
StatePublished - Mar 1 2018

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Immunotherapy of myelodysplastic syndrome: You can run, but you can't hide'. Together they form a unique fingerprint.

Cite this